Lv1
10 积分 2025-06-21 加入
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
3小时前
待确认
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
3小时前
已完结
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
4小时前
已完结
Cancer immunoediting and resistance to T cell-based immunotherapy
9小时前
已完结
皖公网安备34019202002308
